HDC projects
HDC conducts Real World Evidence (RWE) commissioned research projects where data analytics and AI is applied to health data for deeper insights to be used by health care organisations and companies. The research projects at HDC are carried out in collaboration with healthcare authorities, regions, municipalities and pharmaceutical companies.
Value proposition for healthcare organisations
By participating in the HDC, regions and municipalities can:
- Increase their ability to analyse outcomes, cost and compliance per diagnosis, cohort or organisation.
- Plan strategic and prioritise between implementation & change initiatives as well as monitoring these.
- Benchmark against other regions & municipalities.
Type of projects
The data used in the projects is handled in a secure and confidential manner. The projects are:
- Feasibility studies
- Descriptive projects – analysis of the patient journey regarding care consumption, carbon footprint and guidelines & care processes
- Predictive projects – analysis and models on population and individual level, supporting decision making in healthcare
- Adaptation of algorithms and implementation projects
Compliance
All projects at HDC go through an ethical approval. The projects follow the data access approval and data handling required by each healthcare organisation. The software that is used meets or exceeds the legal, ethical and professional standards applicable. For example the General Data Protection Regulation (GDPR), patientdatalagen (PDL) and ISO 27001 Information Security Management.
More about the platform and data infrastructure:
Current collaboration with the industry
Current commissioned research projects at HDC are done in collaboration with the following pharmaceutical companies (March 2022): Astra Zeneca, Pfizer, Novo Nordisk, Novartis, Air Liquide, Takeda, Bristol Myers Squibb and Rubin Medical.
